Esphera SynBio
Berkeley, United States· Est.
Engineered exosome platform for personalized cancer immunotherapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Engineered exosome platform for personalized cancer immunotherapy.
OncologyImmunology
Technology Platform
Engineered transgenes encode multimeric proteins that traffic into budding exosomes, allowing surface targeting domains and luminal cargo (proteins, RNAs) to be packaged for therapeutic delivery.
Opportunities
Scalable, patient‑specific cancer vaccines and exosome‑based delivery of RNA therapeutics across oncology and immunology.
Risk Factors
Technical translation of engineered exosomes, regulatory pathways for vesicle‑based therapies, and competition from larger exosome platforms.
Competitive Landscape
Competes with exosome biotech firms such as Codiak and Exosome Therapeutics; differentiation stems from its synthetic‑biology transgene approach for in‑vivo exosome production.